LumiraDx to Present on Impact of Its Next-Generation Microfluidic Technology at AACC 2022
By LabMedica International staff writers Posted on 20 Jul 2022 |
LumiraDx (London, UK) will be hosting an industry workshop at the 73rd AACC Annual Scientific Meeting & Clinical Lab Expo that will include data-backed insights on the impact of the company’s advanced microfluidic technology over lateral flow point-of-care antigen tests, and the role of these rapid immunoassays in response to the COVID-19 pandemic.
Speaking during the session will be lead author on a number of research papers reviewing the SARS-CoV-2 Ag test, Paul Drain, MD, MPH, FIDSA, Associate Professor in the Departments of Global Health, Medicine (Infectious Diseases), and Epidemiology at the University of Washington, along with Brian DuChateau, Ph.D., D (ABMLI), VP of Clinical and Scientific Affairs, LumiraDx. Key findings in the study revealed that the LumiraDx SARS-CoV-2 Ag test showed a 97.6% positive agreement to RT PCR in patients up to 12 days following symptom onset, and 100% PPA up to Ct 33.
In addition to hosting the workshop, LumiraDx will be exhibiting in the show’s main exhibition hall at booth #4821, and will be presenting its poster abstract ‘Correlation of the Rapid, Point-of-Care LumiraDx SARS-CoV-2 Antibody Test to Other SARS-CoV-2 Antibody Tests and to Viral Neutralization’ (poster B-195) and be featured in a poster abstract by John’s Hopkins Hospital ‘Implementation of POCT COVID-19 Testing Using a LumiraDx SARS-CoV-2 Testing Platform in Patient and Employee Testing Environments’ (poster A-142.)
“Studies have shown that point of care antigen tests with sufficient sensitivity and specificity can facilitate diagnosis, treatment, and mitigate reliance on slower, conventional laboratory-based testing and infrastructure,” said Dr. DuChateau. “However, the COVID-19 pandemic not only demonstrated the need for this type of testing, but also showed how quick result turn-around-time can mitigate rates of infection. LumiraDx’s actively controlled microfluidic testing technology brings lab-comparable performance to the point-of-need, supporting several unique use-cases during the pandemic and beyond.”
Related Links:
LumiraDx
Latest AACC 2022 News
- AACC 2022 Review: International Meetings Rebound After Suffering Long COVID Hiatus
- Faster Method Diagnoses Pediatric Urinary Tract Infections
- Tianlong Showcases Integrated PCR Lab Solutions at AACC 2022
- Cellavision Introduces New Workflow Solution for Low-Volume Hematology Labs at AACC 2022
- Advanced Instruments Introduces New Automated Osmometer at AACC 2022
- Innovative Smartphone and AI-Based Tests Featured at AACC 2022
- New Tests Presented at AACC 2022 to Solve Challenges in Children's Healthcare
- 10-Minute Sepsis Risk Stratification Test Introduced at AACC 2022
- New System Combining DNA/RNA Extraction and Smart PCR Setup Launched at AACC 2022
- Novel Small Volume Blood Collection Device Launched at AACC 2022
- AACC Disruptive Technology Award Finalists Tackle Cancer, Women's Health, and STDs
- Meridian Demonstrates State-of-the-Art Urea Breath Test System at AACC 2022
- Nikon Instruments Displays Latest Clinical Pathology Products at AACC 2022
- Seegene Showcases Latest Molecular Testing Solutions at AACC 2022
- Werfen Introduces New Acute Care Diagnostic Products for CVOR at AACC 2022
- PerkinElmer Demonstrates Vanadis NIPT Screening Platform Featuring Groundbreaking cfDNA Technology